Case control study to evaluate the effectiveness of the 4CMenB vaccine for protection against invasive meningococcal disease caused by group B Neisseria meningitidis in Portugal
Latest Information Update: 09 Dec 2020
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary)
- Indications Meningococcal group B infections
- Focus Therapeutic Use
- Acronyms PT-BEST
Most Recent Events
- 01 Dec 2020 Results published in the JAMA: the Journal of the American Medical Association
- 03 Jul 2019 Planned End Date changed from 1 Jun 2019 to 1 Sep 2019.
- 03 Jul 2019 Status changed from completed to recruiting.